Value
3.5/10data confidence 20%| Component | Sub-score |
|---|---|
| P/S | 3.5 |
SCTX · Why this verdict
Why Scribe Therapeutics (SCTX) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score4.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Scribe Therapeutics is a speculative biotech with heavy insider buying and large analyst-implied upside, but it sits below the market-cap floor and its revenue is shrinking.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Insiders bought $71.3M of stock across 9 purchases in 90 days with zero sales, equal to 18.8% of market cap. Insider | Insider activity should stay net positive over the next 12 months if management conviction holds. | ↓Deteriorating |
| CounterLarge insider purchases in a pre-revenue biotech may reflect financing participation rather than a view on valuation. | ||
The $48.45 analyst target is 141.3% above the $20.08 price, a gap that gives a 9.4 reward-to-risk ratio. Analyst target | Price should converge toward the analyst target as clinical and financing milestones are delivered. | ↓Deteriorating |
| CounterAnalyst targets for pre-revenue biotechs depend on binary trial outcomes, and the stock is already down 49% from its 52-week high. | ||
At a $380M market cap the company sits below the $400M minimum, so it is outside the investable universe. Bear case | The market cap should need to clear $400M before the stock qualifies for a full verdict. | ↑Improving |
| CounterThe shortfall is only 5%, and a modest price rise would lift the company above the floor. | ||
Quarterly revenue fell to $1.9M in the June 2026 quarter from $4.9M a year earlier, a decline of about 61%. Revenue quarters | Revenue should stabilize or grow as new partnerships replace expiring revenue. | ↓Deteriorating |
| CounterRevenue is small relative to the loss per share, so the decline matters less than the cash runway and trial progress. | ||
The latest quarter lost $2.62 per share against an estimate of -$3.72, a 29.5% beat on a smaller loss. Last 4 quarters | Losses should continue to come in at or better than estimates at the next report on Nov 11. | ↓Deteriorating |
| CounterOnly one quarter of history exists, so a single beat is not evidence of a trend. | ||
Insiders bought $71.3M of stock across 9 purchases in 90 days with zero sales, equal to 18.8% of market cap.
↓DeterioratingInsider
- Expectation
- Insider activity should stay net positive over the next 12 months if management conviction holds.
CounterLarge insider purchases in a pre-revenue biotech may reflect financing participation rather than a view on valuation.
The $48.45 analyst target is 141.3% above the $20.08 price, a gap that gives a 9.4 reward-to-risk ratio.
↓DeterioratingAnalyst target
- Expectation
- Price should converge toward the analyst target as clinical and financing milestones are delivered.
CounterAnalyst targets for pre-revenue biotechs depend on binary trial outcomes, and the stock is already down 49% from its 52-week high.
At a $380M market cap the company sits below the $400M minimum, so it is outside the investable universe.
↑ImprovingBear case
- Expectation
- The market cap should need to clear $400M before the stock qualifies for a full verdict.
CounterThe shortfall is only 5%, and a modest price rise would lift the company above the floor.
Quarterly revenue fell to $1.9M in the June 2026 quarter from $4.9M a year earlier, a decline of about 61%.
↓DeterioratingRevenue quarters
- Expectation
- Revenue should stabilize or grow as new partnerships replace expiring revenue.
CounterRevenue is small relative to the loss per share, so the decline matters less than the cash runway and trial progress.
The latest quarter lost $2.62 per share against an estimate of -$3.72, a 29.5% beat on a smaller loss.
↓DeterioratingLast 4 quarters
- Expectation
- Losses should continue to come in at or better than estimates at the next report on Nov 11.
CounterOnly one quarter of history exists, so a single beat is not evidence of a trend.
Per-dimension breakdown
Quality
1.5/10data confidence 57%| Component | Sub-score |
|---|---|
| Net margin | 0.0 |
| Current ratio | 2.3 |
| Moat | 3.8 |
| Piotroski F | 0.0 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 0/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.8 |
| OBV | 10.0 |
| MA position | 2.5 |
| Volume | 1.3 |
- ▸Volume accumulation (rising OBV)
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 225%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
2.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.7 |
| quality rank | 0.1 |
| growth rank | 1.3 |
Technical
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.0 |
| support resistance | 5.3 |
| 52w position | 0.0 |
| gap | 5.0 |
Risk (lower is worse)
4.5/10data confidence 40%| Component | Sub-score |
|---|---|
| days to cover | 8.9 |
| volatility | 0.0 |
Catalyst
7.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 5.0 |
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Market cap $332M below $400M minimum. Not in investable universe.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:MARKET_CAPPassed (5)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:4.4<4.5
Warning (2)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 44 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -56% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The HOLD_IF_HOLDING verdict reflects the MOMENTUM gate's 4.4<4.5 outcome against Insider at 7.3 and asymmetric R:R of 0.00.
The strongest dimensions are Insider at 7.3, Catalyst at 7.0, and Sentiment at 6.6; the weakest are Quality at 1.5, Peer rank at 2.8, and Value at 3.5. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying Conviction
Trip ifNet insider selling exceeds $5M over any 90-day window.
- P2Analyst Target Implies Large Upside
Trip ifAnalyst target falls below $30 from the current $48.45.
- P3Market Cap Below Universe Floor
Trip ifMarket cap stays below $400M for 2 consecutive quarters.
- P4Collaboration Revenue Shrinking
Trip ifQuarterly revenue falls below $1M from the latest $1.9M.
- P5Narrowing Loss Versus Estimates
Trip ifEPS surprise falls below -10% at the next earnings report.